Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 févr. 2026 16h05 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal...
06 févr. 2026 07h30 HE | Source: Plains All American Pipeline, L.P.; Plains GP Holdings

Plains All American Reports Fourth-Quarter and Full-Year 2025 Results

HOUSTON, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported fourth-quarter and full-year 2025 results, announced...
06 févr. 2026 06h13 HE | Source: Janssen Cilag International NV

Johnson & Johnson reçoit un avis favorable du CHMP pour AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2

AMPLITUDE est le premier essai clinique à évaluer des thérapies potentielles pour les patients atteints de CPHSm et d’altérations connues des gènes HRR. Les résultats démontrent un bénéfice clinique...
06 févr. 2026 06h13 HE | Source: Janssen Cilag International NV

Johnson & Johnson erhält vom CHMP einen positiven Bescheid für AKEEGA® (Niraparib- und Abirateronacetat-Tablette mit zweifacher Wirkung) zur Behandlung von metastasiertem hormonsensiblen Prostatakrebs (mHSPC) mit BRCA1/2-Mutationen

AMPLITUDE ist die erste klinische Studie für die Evaluation potenzieller Therapien für Patienten mit mHSPC und bekannten HRR-Genveränderungen, einschließlich positiver Ergebnisse, welche die...
03 févr. 2026 09h00 HE | Source: Arax Investment Partners

Arax Investment Partners Acquires $1.5 Billion GFP Private Wealth

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- In a move to expand its foothold in the Midwest, Arax Investment Partners (“Arax”), a premier wealth management firm, has acquired GFP Private Wealth...
30 janv. 2026 07h19 HE | Source: Janssen Cilag International NV

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen...
16 janv. 2026 10h50 HE | Source: Baylor Genetics

Baylor Genetics Supports Bipartisan House Bill to Broaden Medicaid Access to Genomic Sequencing for Children who Meet Medical Criteria

HOUSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, announced its support for the Genomic Answers for Children’s Health...
08 janv. 2026 16h34 HE | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
08 janv. 2026 16h05 HE | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
05 déc. 2025 08h00 HE | Source: Lelantos Holdings, Inc.

Lelantos Holdings Engages Aloba, Awomolo & Partners as PCAOB-Approved Auditor to Support Planned Uplift to OTCQB

TUCSON, Ariz., Dec. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Lelantos Holdings, Inc. (OTCID: LNTO) (“Lelantos” or the “Company”), a diversified development company focused on renewable energy and...

Page suivante